Theravance Biopharma, Inc. $TBPH Shares Sold by Newtyn Management LLC

Newtyn Management LLC trimmed its holdings in Theravance Biopharma, Inc. (NASDAQ:TBPH) by 29.1% during the 2nd quarter, Holdings Channel.com reports. The firm owned 3,434,191 shares of the biopharmaceutical company’s stock after selling 1,407,438 shares during the period. Theravance Biopharma accounts for 7.4% of Newtyn Management LLC’s holdings, making the stock its 2nd biggest holding. Newtyn Management LLC owned approximately 0.07% of Theravance Biopharma worth $58,381,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Quarry LP purchased a new position in shares of Theravance Biopharma during the 3rd quarter valued at about $26,000. Caitong International Asset Management Co. Ltd boosted its stake in shares of Theravance Biopharma by 107.4% in the third quarter. Caitong International Asset Management Co. Ltd now owns 2,725 shares of the biopharmaceutical company’s stock worth $40,000 after buying an additional 1,411 shares during the last quarter. Tower Research Capital LLC TRC grew its holdings in Theravance Biopharma by 18.5% during the second quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock worth $55,000 after acquiring an additional 781 shares during the period. CIBC Private Wealth Group LLC grew its holdings in Theravance Biopharma by 20,269.6% during the third quarter. CIBC Private Wealth Group LLC now owns 4,685 shares of the biopharmaceutical company’s stock worth $68,000 after acquiring an additional 4,662 shares during the period. Finally, AQR Capital Management LLC purchased a new position in Theravance Biopharma during the first quarter valued at approximately $101,000. 99.10% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, SVP Rhonda Farnum sold 13,314 shares of the business’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $16.39, for a total value of $218,216.46. Following the completion of the sale, the senior vice president owned 232,457 shares of the company’s stock, valued at approximately $3,809,970.23. The trade was a 5.42% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, major shareholder Eli Samaha sold 273,871 shares of the business’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $17.23, for a total transaction of $4,718,797.33. Following the completion of the sale, the insider directly owned 9,237,279 shares of the company’s stock, valued at approximately $159,158,317.17. The trade was a 2.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 350,011 shares of company stock worth $6,008,309 in the last quarter. Insiders own 7.65% of the company’s stock.

Analyst Ratings Changes

TBPH has been the subject of a number of analyst reports. Weiss Ratings raised Theravance Biopharma from a “hold (c)” rating to a “hold (c+)” rating in a report on Monday, August 17th. Wall Street Zen cut shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. JonesTrading lowered shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a report on Monday, June 29th. BTIG Research cut shares of Theravance Biopharma from a “buy” rating to a “neutral” rating in a research note on Monday, June 29th. Finally, Zacks Research upgraded shares of Theravance Biopharma from a “hold” rating to a “strong-buy” rating in a research note on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating and seven have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $19.40.

Theravance Biopharma Price Performance

Shares of Theravance Biopharma stock opened at $17.05 on Monday. Theravance Biopharma, Inc. has a twelve month low of $13.08 and a twelve month high of $21.03. The business has a 50-day moving average price of $16.96 and a 200 day moving average price of $16.61. The firm has a market cap of $885.24 million, a PE ratio of 16.88 and a beta of 0.19.

Theravance Biopharma (NASDAQ:TBPH) last released its quarterly earnings results on Monday, August 10th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.18). The business had revenue of $20.73 million during the quarter, compared to analyst estimates of $22.49 million. Theravance Biopharma had a negative return on equity of 0.77% and a net margin of 51.58%. On average, sell-side analysts expect that Theravance Biopharma, Inc. will post 1.56 EPS for the current year.

Theravance Biopharma Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.